MedTrace Logo

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

NCT01866293 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-08-30

Study results available
· View outcomes & findings →

Summary

This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.

Conditions

Interventions

DRUG

Cabozantinib (XL184)

Sponsors & Collaborators

Principal Investigators

  • Sergio Giralt, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-28
Primary Completion
2016-08-18
Completion
2016-08-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01866293 on ClinicalTrials.gov